Drug Therapy
Drugs are approved in the U.S. by the Food and Drug Administration (FDA) for specific purposes to help guide medical practice.
Related Resources
NEW Criteria! Groundbreaking Trial for HHT: Learn About Pazopanib (Recorded)
Webinar – 2024Your questions answered about our newest clinical trial with NEW expanded criteria! Join Cassi Friday, PhD and Jim Gossage, MD as they explain who is now eligible, what Pazopanib is, and how you can get involved!
More
Pazopanib: A Groundbreaking Trial for HHT (Recording)
Webinar – 2023Get your questions answered about our newest clinical trial! Join Cassi Friday, PhD and Jim Gossage, MD as they explain who is eligible, what Pazopanib is and how you can get involved!
MoreAbstracts – 14th HHT International Scientific Conference (2022)
Scientific Literature – 2023Angiogenesis. This article is open access and free for a certain period of time; otherwise, it is available for purchase directly from the publisher. Click to view resource.
MoreExecutive Summary – 14th HHT International Scientific Conference (2022)
Scientific Literature – 2023Angiogenesis. This article is open access and free for a certain period of time; otherwise it is available for purchase directly from the publisher. Click to view resource.
More
Bedside to Bench: How the HHT Community Drives Research Initiatives (Recorded)
Webinar – 2021In March 2020, Cure HHT was 1 of 30 organizations selected to participate in the Chan Zuckerberg Initiative (also known as CZI) Rare is One Project. This ambitious project is lifting up the work that patient communities are doing to accelerate resear…
More
Nuts and Bolts of A Clinical Trial – the PATH-HHT Study (Recorded)
Webinar – 2021Research is the key to the future health and quality of life for HHT patients. “Diseases can only be cured when scientists understand them. This understanding, which comes from basic research, leads to new drugs and treatments.” ~Dr. Christopher Hugh…
More
International HHT Guidelines – Overview (Recorded)
Webinar – 2021Join Dr. Marie Faughnan, Director, Toronto HHT Centre of Excellence as she provides an overview of the newly updated International HHT Guidelines and how they are used to set the standard of care globally for the diagnosis and treatment of HHT. Dr. F…
MoreBevacizumab (Avastin) Use In HHT
Policy Statement – 2020Hereditary hemorrhagic telangiectasia (HHT, also known as OslerWeber-Rendu Syndrome) is a condition that is characterized by focal proliferation of blood vessels (vascular malformations) in multiple organs. Two of the most commonly affected organs in…
MoreBevacizumab for treating HHT patients with severe hepatic involvement or refractory anemia
Scientific Literature – 2020PLoS One. Authors: Carolina Vázquez, María Laura Gonzalez, Augusto Ferraris, Juan Carlos Bandi, and Marcelo Martín Serra. This article is available for public use and does not require purchase. Click to view the full article.
More
The Science Behind the 2019 Scientific Conference (recorded)
Webinar – 2020Philippe Marambaud, PhD and Andy White, MD discuss important advances in HHT research which were presented at the 2019 HHT International Scientific Conference in Puerto Rico. Learn about advancements in drug therapies for bleeding, screening and trea…
More
Future Treatments for Hereditary Hemorrhagic Telangiectasia
Scientific Literature – 2020Orphanet Journal of Rare Diseases. Authors: Florian Robert, Agnès Desroches-Castan, Sabine Bailly, Sophie Dupuis-Girod and Jean-Jacques Feige. This article is available for public use and does not require purchase. Click to view the full article.
MoreSystemic bevacizumab for high-output cardiac failure in HHT: an international survey of HHT centers
Scientific Literature – 2019Orphanet Journal of Rare Diseases. Authors: Hanny Al-Samkari, Hasan A. Albitar, Scott E. Olitsky, Marianne S. Clancy and Vivek N. Iyer. This article is available for public use and does not require purchase. Click to view the full article.
MoreSystemic bevacizumab for the treatment of chronic bleeding in HHT
Scientific Literature – 2018Journal of Internal Medicine. Authors: Al-Samkari, H., Kritharis, A., Rodriguez-Lopez, J.M., and Kuter, D.J. This article can be purchased directly from the publisher. Click to view the article description and purchase options.
MoreEndoglin Interacts with VEGFR2 to Promote Angiogenesis
Scientific Literature – 2018Angiogenesis is the physiologic process by which new blood vessels arise from pre-existing vessels. Endoglin, a TGF-β coreceptor predominantly expressed in endothelial cells, plays an important role in vascular development and tumor-associated angiog…
MoreEndoglin Interacts with VEGFR2 to Promote Angiogenesis
Scientific Literature – 2018The FASEB Journal. Authors: Hongyu Tian, Jennifer J. Huang, Christelle Golzio, Xia Gao, Melissa Hector-Greene, Nicholas Katsanis, and Gerard C. Blobe. This article is available for public use and does not require purchase. Click to view the full arti…
MoreRelated News
A Monumental $128 Million Step Forward for HHT Research
Today is a monumental day for HHT. The new biotechnology company, Diagonal Therapeutics, officially launched and we wanted to share more about why this is news you simply can’t miss! In short, Diagona…
2024 National HHT Patient & Physician Conference
November 28, 2023
Help save lives this Giving Tuesday
November 23, 2023
Webinar – Pazopanib: A Groundbreaking Trial for HHT (Recording)
November 17, 2023
Seattle National Conference
May 13, 2023